Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2023

Open Access 01-12-2023 | Leukodystrophy | Review

A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel

Authors: Nigel Armstrong, Andrew Olaye, Caro Noake, Francis Pang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2023

Login to get access

Abstract

Objective

To understand the benefit-risk profile for historical and current treatments for MLD.

Methods

A systematic review was conducted on the effectiveness, safety, and costs of MLD treatments: allogeneic haematopoietic stem cell transplantation (HSCT) and atidarsagene autotemcel (arsa-cel) according to best practice.

Results

A total of 6940 titles and abstracts were retrieved from the literature searches and 26 from other sources. From these, 35 manuscripts reporting on a total of 12 studies were selected for inclusion in the review. There were no controlled multi-armed trials. However, we provide observations comparing two interventional therapies (alloHSCT and arsa-cel) and each of these to standard/supportive care (natural history). There were no benefits for survival, gross motor function and cognitive function for LI patients receiving alloHSCT, as patients experienced disease progression similar to LI natural history. For juvenile patients receiving alloHSCT, no differences in survival were observed versus natural history, however stabilisation of cognitive and motor function were reported for some patients (particularly for pre- or minimally-symptomatic LJ patients), while others experienced disease progression. Furthermore, alloHSCT was associated with severe complications such as treatment-related mortality, graft versus host disease, and re-transplantation in both LI and EJ treated patients. Most LI and EJ patients treated with arsa-cel appeared to have normal development, preservation, or slower progression of gross motor function and cognitive function, in contrast to the rapid decline observed in natural history patients. A survival benefit for arsa-cel versus natural history and versus alloHSCT was observed in LI patients.LI and EJ patients treated with arsa-cel had better gross motor function and cognitive function compared to alloHSCT, which had limited effect on motor and cognitive decline. No data has been reported for arsa-cel treatment of LJ patients.

Conclusions

Overall, this systematic review indicates that compared to NHx and HSCT, treatment with arsa-cel results in clinically relevant benefits in LI and EJ MLD patients by preserving cognitive function and motor development in most patients, and increased survival for LI patients. Nevertheless, further research is required to confirm these findings, given they are based on results from non-RCT studies.
Appendix
Available only for authorised users
Literature
1.
NIHR Innovation Observatory: OTL-200 for metachromatic leukodystrophy: health technology briefing, June 2019 [Internet]. Leeds: NIHR, 2019. Accessed 6 Nov 2019.
2.
3.
Kehrer C, Elgun S, Raabe C, Bohringer J, Beck-Wodl S, Bevot A, Kaiser N, Schols L, Krageloh-Mann I, Groeschel S. Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology. 2021;96(2):e255–66.CrossRefPubMed
4.
Kehrer C, Blumenstock G, Gieselmann V, Krageloh-Mann I. The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol. 2011;53(9):850–5.CrossRefPubMed
5.
Kehrer C, Kustermann-Kuhn B, Raabe C, Krageloh-Mann I. Natural history of metachromatic leucodystrophy (MLD): clinical course. Eur J Pediatr. 2008;167(3):374.
6.
Noyes J, Godfrey C, Beecham J. Resource use and service costs for ventilator-dependent children and young people in the UK. Health Soc Care Commun. 2006;14(6):508–22.CrossRef
7.
Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic stem cell transplantation in inborn errors of metabolism. Front Pediatr. 2019;7:6.CrossRef
8.
Beschle J, Döring M, Kehrer C, Raabe C, Bayha U, Strölin M, Böhringer J, Bevot A, Kaiser N, Bender B. Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy. Mol Cell Pediatr. 2020;7(1):1–9.CrossRef
9.
10.
Centre for Reviews and Dissemination: Systematic reviews: CRD’s guidance for undertaking reviews in health care. York: University of York, 2009. Accessed 23 Mar 2011.
11.
12.
13.
Fumagalli F, Calbi V, Sora MGN, Sessa M, Baldoli C, Rancoita PMV, Ciotti F, Sarzana M, Fraschini M, Zambon AA, Acquati S, Redaelli D, Attanasio V, Miglietta S, Mattia FD, Barzaghi F, Ferrua F, Migliavacca M, Tucci F, Gallo V, Carro UD, Canale S, Spiga I, Lorioli L, Recupero S, Fratini ES, Morena F, Silvani P, Calvi MR, Facchini M, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399(10322):372–83.CrossRefPubMedPubMedCentral
14.
The Joanna Briggs Institute: checklist for cohort studies: The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews. Adelaide: JBI, 2017. Accessed 19 Nov 2019.
15.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral
16.
Groeschel S, Kuhl JS, Bley AE, Kehrer C, Weschke B, Doring M, Bohringer J, Schrum J, Santer R, Kohlschutter A, Krageloh-Mann I, Muller I. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol. 2016;73(9):1133–40.CrossRefPubMed
17.
van Rappard DF, Boelens JJ, van Egmond ME, Kuball J, van Hasselt PM, Oostrom KJ, Pouwels PJ, van der Knaap MS, Hollak CE, Wolf NI. Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience. Blood. 2016;127(24):3098–101.CrossRefPubMed
18.
Bley A, Muller I, Lobel U, Schrum J, Santer R, Hartmann M, Kohlschutter A. Hematopoietic stem cell transplantation (HSCT) in nine patients with juvenile MLD. Neuropediatrics. 2013;44(2):PS14_1097.CrossRef
19.
Bohringer J, Kustermann-Kuhn B, Gieseke F, Erbacher A, Doring M, Kehrer C, Lang P, Krageloh-Mann I, Handgretinger R, Muller I. Hematopoietic stem cell therapy in eight patients with metachromatic leukodystrophy relevance of post-transplant medication [Abstract 3727]. Presented at American Society of Hematology Annual Meeting and Exposition 2010; 4 Dec 2010; Orlando: US. 2010.
20.
Singh J, Simmons L, Chakrapani A, Wassmer E. Metachromatic leukodystrophy: mortality data to support counselling of parents. J Inherit Metab Dis. 2012;35(1 Suppl 1):S107.
21.
Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, Orchard PJ. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10:94.CrossRefPubMedPubMedCentral
22.
van den Broek BTA, Page K, Paviglianiti A, Hol J, Allewelt H, Volt F, Michel G, Diaz MA, Bordon V, O’Brien T, Shaw PJ, Kenzey C, Al-Seraihy A, van Hasselt PM, Gennery AR, Gluckman E, Rocha V, Ruggeri A, Kurtzberg J, Boelens JJ. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018;2(1):49–60.CrossRefPubMedPubMedCentral
23.
Martin HR, Poe MD, Provenzale JM, Kurtzberg J, Mendizabal A, Escolar ML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant. 2013;19(4):616–24.CrossRefPubMed
24.
Prasad VK, Mendizabal A, Parikh SH, Szabolcs P, Driscoll TA, Page K, Lakshminarayanan S, Allison J, Wood S, Semmel D, Escolar ML, Martin PL, Carter S, Kurtzberg J. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood. 2008;112(7):2979–89.CrossRefPubMedPubMedCentral
25.
Fumagalli F, Zambon AA, Rancoita PMV, Baldoli C, Canale S, Spiga I, Medaglini S, Penati R, Facchini M, Ciotti F, Sarzana M, Lorioli L, Cesani M, Natali Sora MG, Del Carro U, Cugnata F, Antonioli G, Recupero S, Calbi V, Di Serio C, Aiuti A, Biffi A, Sessa M. Metachromatic leukodystrophy: a single-center longitudinal study of 45 patients. J Inherit Metab Dis. 2021;44(5):1151–64.CrossRefPubMed
26.
Kehrer C, Groeschel S, Kustermann-Kuhn B, Burger F, Kohler W, Kohlschutter A, Bley A, Steinfeld R, Gieselmann V, Krageloh-Mann I, German L. Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. Orphanet J Rare Dis. 2014;9:18.CrossRefPubMedPubMedCentral
27.
Muhlstein A, Gelperina S, Shipulo E, Maksimenko O, Kreuter J. Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy–physicochemical evaluation. Pharmazie. 2014;69(7):518–24.PubMed
28.
Orchard Therapeutics: A phase I/II clinical trial of haematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy (Interim Report No. 2.2). Clinical study report {201222/v.2.2} [PDF provided by Orchard]. Orchard Therapeutics, 30th September 2019. Aaccessed 14 April 2020.
29.
Orchard Therapeutics. Clinical study report for expanded access programmes (EAPs) for haematopoietic stem cell gene therapy OTL-200-F (formerly known as GSK2696274) in early onset metachromatic leukodystrophy (MLD) patients. Hospital exemption (HE) protocol 20529 and compassionate use program (CUP) 206258. 205029–206258 vl.0 [PDF provided by Orchard]. Orchard Therapeutics, 1st October 2019. Accessed 14 April 2020.
30.
Ready RE, Ott BR, Grace J, Fernandez I. The Cornell-Brown scale for quality of life in dementia. Alzheimer Dis Assoc Disord. 2002;16(2):109–15.CrossRefPubMed
31.
Musolino PL, Lund TC, Pan J, Escolar ML, Paker AM, Duncan CN, Eichler FS. Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature. Neuropediatrics. 2014;45(3):169–74.CrossRefPubMedPubMedCentral
32.
Mahmood A, Berry J, Wenger DA, Escolar M, Sobeih M, Raymond G, Eichler FS. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25(5):572–80.CrossRefPubMed
Metadata
Title
A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
Authors
Nigel Armstrong
Andrew Olaye
Caro Noake
Francis Pang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2023
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-023-02814-2

Other articles of this Issue 1/2023

Orphanet Journal of Rare Diseases 1/2023 Go to the issue

Review

The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review

Review

Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

Research

Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases

Research

Higher rates of non-skeletal complications and greater healthcare needs in achondroplasia compared to the general UK population: a matched cohort study using the CPRD database

Research

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative

Research

Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients